Press

Press

2021-11-30 14:36 Acarix offentliggör prospekt i samband med företrädesemission om cirka 79 MSEK Regulatory
2021-11-30 14:36 Acarix publishes prospectus in connection with rights issue of approximately SEK 79 million Regulatory
2021-11-23 14:30 Kommuniké från extra bolagsstämma i Acarix Regulatory
2021-11-23 14:30 Announcement from Acarix's extra general meeting Regulatory
2021-11-11 08:00 Acarix AB (publ) publishes Interim Report, January – September 2021 Regulatory
2021-11-11 08:00 Acarix AB (publ) publicerar delårsrapport, januari – september 2021 Regulatory
2021-11-09 08:00 Acarix accelerates US market entry with Proximo Medical as commercialization partner Regulatory MAR
2021-11-08 17:30 Acarix US expansion to be a major contributor to the company’s new financial and operational goals Regulatory MAR
2021-11-05 10:00 Kallelse till extra bolagsstämma i Acarix AB Regulatory
2021-11-05 10:00 Notice of Extra General Meeting in Acarix AB Regulatory
2021-11-05 08:00 Acarix decides on a fully guaranteed rights issue of approximately SEK 79,3 million to expand on the US market Regulatory MAR
2021-11-05 08:00 Acarix beslutar om en fullt garanterad företrädesemission om cirka 79,3 MSEK för att expandera på USA-marknaden Regulatory MAR
2021-10-27 08:00 Acarix granted US CPT reimbursement code for CADScor System Regulatory MAR
2021-09-28 15:00 ACARIX begins US expansion and appoints Helen Ljungdahl Round as President Acarix Inc
2021-09-14 13:00 Acarix inleder USA expansion och utser USA-chef
2021-09-14 13:00 Acarix begins US expansion and appoints US President
2021-09-07 14:00 New health economic study proves the value of CADScor® in coronary disease diagnostics
2021-09-07 14:00 Ny sjukvårdsekonomisk studie lägger fram bevis för värdet av CADScor® vid diagnostik av kranskärlssjukdom
2021-08-27 11:33 Initial Dan-NICAD II results presented today at ESC
2021-08-27 11:33 Första resultaten från Dan-NICAD II presenteras idag på ESC
2021-08-23 12:00 Preliminary Dan-NICAD II results to be presented at ESC
2021-08-23 12:00 Preliminärt Dan-NICAD II-resultat presenteras på ESC
2021-08-19 08:00 Acarix AB (publ) publishes Interim Report, January – June 2021 Regulatory
2021-08-19 08:00 Acarix AB (publ) publicerar delårsrapport, januari – juni 2021 Regulatory
2021-05-11 13:00 Acarix AB (publ) publicerar delårsrapport, januari - mars 2021 Regulatory
2021-05-11 13:00 Acarix AB (publ) publishes Interim Report, January – March 2021 Regulatory
2021-05-11 11:50 Announcement from Acarix's annual general meeting Regulatory
2021-05-11 11:50 Kommuniké från årsstämman i Acarix Regulatory
2021-04-20 13:00 Acarix publicerar årsredovisningen för 2020 Regulatory
2021-04-20 13:00 Acarix publishes the annual report for 2020 Regulatory
PreviousNext

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid AI-based Coronary Artery Disease (CAD) rule-out.

The CE-mark approved and FDA De Novo cleared Acarix CADScor®System is for patients experiencing stable chest pain with suspected CAD and is designed to help reduce millions of unnecessary and costly diagnostic procedures.2 CADScor®System calculates a patient-specific CAD-score non-invasively in 10 minutes with at least 96% confidence (Negative Predictive Value).¹

Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX).

Learn more
  1. User manual US-FDA v.12.Y, prevalence 10,7%
  2. Shaw LJ, Marwick TH, Zoghbi WA, Hundley WG, Kramer CM, Achenbach S, Dilsizian V, Kern MJ, Chandrashekhar Y, Narula J. Why all the focus on cardiac imaging? JACC Cardiovasc Imaging. 2010 Jul;3(7):789-94. doi: 10.1016/j.jcmg.2010.05.004. PMID: 20633864.